Publicaciones en las que colabora con ESTELA NATIVIDAD PAZ ARTAL (23)

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Age-dependent association of clonal hematopoiesis with COVID-19 mortality in patients over 60 years

    GeroScience, Vol. 45, Núm. 1, pp. 543-553

  3. Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5-adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients

    Transplantation Direct, Vol. 9, Núm. 10, pp. E1536

2022

  1. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. A short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID

    Biomedicines, Vol. 9, Núm. 11

  2. Alterations in circulating monocytes predict covid-19 severity and include chromatin modifications still detectable six months after recovery

    Biomedicines, Vol. 9, Núm. 9

  3. Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients

    American Journal of Transplantation, Vol. 21, Núm. 12, pp. 3946-3957

  4. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

    International Journal of Infectious Diseases, Vol. 105, pp. 487-494

  5. Discordance Between SARS-CoV-2-specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients

    Transplantation Direct, Vol. 7, Núm. 12, pp. E794

  6. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

    International Journal of Infectious Diseases, Vol. 105, pp. 319-325

  7. IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 5, pp. 1652-1661.e1

  8. Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination

    PLoS Pathogens, Vol. 17, Núm. 12

  9. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 6, pp. 1258-1262

  10. T cell–mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19

    American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2785-2794

2020

  1. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection

    Annals of Hematology

  2. IL-6–based mortality risk model for hospitalized patients with COVID-19

    Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 4, pp. 799-807.e9

2018

  1. Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?

    Atherosclerosis, Vol. 269, pp. 204-210

2017

  1. Complement C3F allotype synthesized by liver recipient modifies transplantation outcome independently from donor hepatic C3

    Clinical Transplantation, Vol. 31, Núm. 1